HF Advisory Group LLC Purchases 18,466 Shares of Pfizer Inc. (NYSE:PFE)

HF Advisory Group LLC increased its position in Pfizer Inc. (NYSE:PFE - Free Report) by 20.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 109,868 shares of the biopharmaceutical company's stock after buying an additional 18,466 shares during the quarter. Pfizer accounts for approximately 1.2% of HF Advisory Group LLC's holdings, making the stock its 21st biggest holding. HF Advisory Group LLC's holdings in Pfizer were worth $2,784,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the company. Long Run Wealth Advisors LLC boosted its holdings in Pfizer by 12.0% in the first quarter. Long Run Wealth Advisors LLC now owns 58,236 shares of the biopharmaceutical company's stock valued at $1,476,000 after acquiring an additional 6,235 shares in the last quarter. Teamwork Financial Advisors LLC lifted its position in shares of Pfizer by 10.3% in the 1st quarter. Teamwork Financial Advisors LLC now owns 50,040 shares of the biopharmaceutical company's stock worth $1,268,000 after purchasing an additional 4,653 shares during the period. Greenfield Savings Bank lifted its position in shares of Pfizer by 4.0% in the 1st quarter. Greenfield Savings Bank now owns 37,333 shares of the biopharmaceutical company's stock worth $946,000 after purchasing an additional 1,451 shares during the period. Apella Capital LLC lifted its position in shares of Pfizer by 6.5% in the 1st quarter. Apella Capital LLC now owns 22,602 shares of the biopharmaceutical company's stock worth $573,000 after purchasing an additional 1,374 shares during the period. Finally, Silverberg Bernstein Capital Management LLC lifted its position in shares of Pfizer by 19.5% in the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 9,800 shares of the biopharmaceutical company's stock worth $248,000 after purchasing an additional 1,600 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

PFE has been the subject of several research analyst reports. Cantor Fitzgerald initiated coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price for the company. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. UBS Group raised their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Finally, Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Stock Up 1.0%

Shares of Pfizer stock traded up $0.24 during trading on Friday, hitting $23.36. The company's stock had a trading volume of 30,404,818 shares, compared to its average volume of 41,016,816. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a fifty day simple moving average of $22.95 and a two-hundred day simple moving average of $25.00. The company has a market capitalization of $132.81 billion, a PE ratio of 16.57, a P/E/G ratio of 0.64 and a beta of 0.57. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer's revenue was down 7.8% compared to the same quarter last year. During the same period last year, the business earned $0.82 EPS. Equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.36%. Pfizer's dividend payout ratio is currently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.